Akrevia’s Aklusion platform, based on technology licensed from City of Hope and Thomas Jefferson University, allows potently active biological molecules to be kept inactive until they encounter the tumor microenvironment.
With a potential best-in-class anti-CTLA4 antibody as validation, the technology is being broadly applied to other biologic architectures, including highly-potent cytokines and chemokines which currently have limited or no clinical utility due to toxicities.
By tailoring pharmacokinetic and pharmacodynamic properties in parallel, Aklusion allows design of molecules with potential best-in-class potency and selectivity.
“Akrevia” is derived from the Greek word for “precision”, which reflects our mission to precisely deliver the activity of potent, tailored immunotherapies exactly where it’s needed.
We are located in Cambridge, MA, funded by blue chip investors F-Prime Capital Partners and Atlas Venture, and led by an experienced management team with a track record of building innovative companies and delivering novel therapies to cancer patients.
We have brought together a team of passionate leaders and investors with deep experience in growing successful companies and delivering breakthrough medicines to cancer patients.